Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern

Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT)

(2021) Cristina Mussini et al.   CLINICAL MICROBIOLOGY AND INFECTION

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19

(2021) Robert L. Gottlieb et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

(2021) Markus Hoffmann et al.   CELL

Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization

(2021) Pengfei Wang et al.   Cell Host & Microbe

Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021

(2021) Tjede Funk et al.   Eurosurveillance

The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies

(2021) Richard Copin et al.   CELL

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

(2021) Delphine Planas et al.   NATURE

Hyperglycemia at Hospital Admission Is Associated With Severity of the Prognosis in Patients Hospitalized for COVID-19: The Pisa COVID-19 Study

(2020) Alberto Coppelli et al.   DIABETES CARE

Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study

(2020) Marco Falcone et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

(2020) David M. Weinreich et al.   NEW ENGLAND JOURNAL OF MEDICINE

Role of Low-Molecular-Weight Heparin in Hospitalized Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia: A Prospective Observational Study

(2020) Marco Falcone et al.   Open Forum Infectious Diseases